{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:50:17Z","timestamp":1789012217138,"version":"build-2803163510"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Multiple myeloma is a disease of elderly adults. Improvement in survival has occurred because of biological insights and novel agents. Therapeutic options involve choices today, thus have become more complex. Demographics have led to an increased number of elderly patients and age may be associated with a poorer outcome but is not the only prognostic predictor today.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>To evaluate patients\u2019 health status rather than their chronological age alone, frailty scores and functional geriatric assessments are used to identify prognostic groups, avoid adverse events, compare clinical trials and tailor treatment. As most clinical trials exclude frail elderly patients, those enrolled therein are often younger and healthier than the typical multiple myeloma patient. This represents a challenge for frail cohorts because of their increased risk of adverse events, overtreatment and undertreatment and\/or therapy discontinuation, which may lead to poorer survival and quality of life (QoL). Reassessing patients\u2019 status via geriatric assessments is also relevant during treatment to adjust interventions appropriately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Integrating geriatric assessments may lead to individual treatment decisions, dose adjustments, better clinical outcome and QoL. Prospective clinical trials that enroll elderly multiple myeloma patients with comorbidities, incorporate frailty scores\/geriatric assessments and help with prognostication, adverse event avoidance and QoL maintenance, remain warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cco.0000000000000792","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T13:54:12Z","timestamp":1631886852000},"page":"648-657","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?"],"prefix":"10.1097","volume":"33","author":[{"given":"Mandy-Deborah","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gengenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of newly diagnosed elderly multiple myeloma patients","volume":"21","author":"Antoine-Pepeljugoski","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","article-title":"Management of multiple myeloma in older adults: gaining ground with geriatric assessment","volume":"8","author":"Wildes","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"R3-20250526","first-page":"CCI.18.00043","article-title":"Development of a medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma","volume":"2","author":"Mian","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ebiom.2019.10.034","article-title":"Skeletal muscle as potential central link between sarcopenia and immune senescence","volume":"49","author":"Nelke","year":"2019","journal-title":"EBioMedicine"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3346\/jkms.2020.35.e16","article-title":"Frailty and comprehensive geriatric assessment","volume":"35","author":"Lee","year":"2019","journal-title":"J Korean Med Sci"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.12837","article-title":"Age disparities in survival from lymphoma and myeloma: a comparison between US and England","volume":"165","author":"Pulte","year":"2014","journal-title":"Br J Haematol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/10428194.2017.1365859","article-title":"Managing multiple myeloma in elderly patients","volume":"59","author":"Diamond","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.16945","article-title":"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, phase III trial","volume":"192","author":"Jackson","year":"2021","journal-title":"Br J Haematol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejh.13530","article-title":"Survival trends in elderly myeloma patients","volume":"106","author":"Jones","year":"2021","journal-title":"Eur J Haematol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/cncr.32978","article-title":"Risk of disease recurrence and survival in patients with multiple myeloma: a German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients","volume":"126","author":"Schinke","year":"2020","journal-title":"Cancer"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.19.02809","article-title":"Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review","volume":"38","author":"DuMontier","year":"2020","journal-title":"J Clin Oncol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/cncr.33658","article-title":"Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort","volume":"127","author":"Scheubeck","year":"2021","journal-title":"Cancer"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jgo.2020.11.003","article-title":"Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation","volume":"12","author":"M\u00f6ller","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.16806","article-title":"Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry","volume":"193","author":"Redder","year":"2021","journal-title":"Br J Haematol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2019-127030","article-title":"The Revised Myeloma Comorbidity Index (R-MCI) as a promising approach for predicting overall (os)- and progression-free (pfs) survival and optimizing therapy strategies in multiple myeloma (mm) patients (pts) - comparative analysis of 5 comorbidity indices (ci), including retro- and prospective applicability","volume":"134","author":"Schoeller","year":"2019","journal-title":"Blood"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM\u2013comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clml.2011.09.216","article-title":"Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal","volume":"12","author":"Kleber","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome","volume":"13","author":"Kleber","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1111\/hdi.12707","article-title":"Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis","volume":"23","author":"K\u00fcchlin","year":"2019","journal-title":"Hemodial Int"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.15800","article-title":"Substratification of patients with newly diagnosed standard-risk multiple myeloma","volume":"185","author":"Binder","year":"2019","journal-title":"Br J Haematol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale","volume":"6","author":"Bonanad","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"R36-20250526","first-page":"121","article-title":"Das Blaue Buch: Chemotherapie-Manual H\u00e4matologie und, Onkologie","author":"Engelhardt","year":"2017"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.3390\/cancers12113106","article-title":"Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients","volume":"12","author":"Bonello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R38-20250526","first-page":"1182","volume":"106","author":"Schjesvold","year":"2021","journal-title":"Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.26172","article-title":"Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","volume":"96","author":"Auner","year":"2021","journal-title":"Am J Hematol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2020.02.018","article-title":"Comparative efficacy of bortezomib, melphalan, and prednisone (VMP) with or without daratumumab versus VMP alone in the treatment of newly diagnosed multiple myeloma: propensity score matching of ALCYONE and VISTA phase III studies","volume":"20","author":"Cavo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2020.38.15_suppl.8501","article-title":"Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"JCO"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:07:59Z","timestamp":1748286479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000792","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}